EICHOR

Recruiting studies: Platinum Sensitive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Phase 2 · 1 location(s) · Akeso · NCT06686030 Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NA · 1 location(s) · The University of Hong Kong · NCT06292286 Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Phase 2 · 1 location(s) · Sheba Medical Center · NCT04519151 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard o
Phase 3 · 186 location(s) · Merck Sharp & Dohme LLC · NCT06824467 Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556 A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving
Phase 2 · 16 location(s) · AbbVie · NCT07024784 A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116 Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Phase 2 · 1 location(s) · National Cancer Center, Korea · NCT07171528 Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06840002 Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Phase 2 · 5 location(s) · Shanghai Gynecologic Oncology Group · NCT03983226 RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06420973 CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Phase 1 · 1 location(s) · Lan Coffman · NCT05942300 Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Phase 2 · 1 location(s) · Chongqing University Cancer Hospital · NCT05551208 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensiti
Phase 3 · 266 location(s) · Eli Lilly and Company · NCT07213804 Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Phase 4 · 1 location(s) · Tang-Du Hospital · NCT06467786 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Tre
Phase 3 · 16 location(s) · Genmab · NCT07225270 An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Phase 2 · 6 location(s) · University of Colorado, Denver · NCT05887609 Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1/Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06040970 A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Phase 1/Phase 2 · 28 location(s) · Compugen Ltd · NCT06888921 Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Phase 2 · 25 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06663098 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Plati
Phase 3 · 2 location(s) · Genmab · NCT07564141 Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE
Phase N/A · 12 location(s) · Pomeranian Medical University Szczecin · NCT06614790 Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122 TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinom
Phase 2 · 14 location(s) · Centre Francois Baclesse · NCT04678362

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →